Calypso Medical Technologies, a developer of real-time localization technology used for the tracking of tumor targets, has entered into a non-exclusive product distribution agreement with Siemens Healthcare for the sale of its Calypso System in Europe.

Under terms of the agreement, Siemens retains non-exclusive rights to sell Calypso's real-time tracking technology to existing and prospective Siemens linear accelerator customers throughout Europe for a period of three years, according to the Seattle-based Calypso.

Last year, Calypso entered into a master development agreement with Siemens to jointly develop products integrating the Calypso System with the Siemens Artiste linear accelerator and other Siemens radiotherapy technologies.